Restaging Transurethral Resection of Bladder Tumor for High-risk Stage Ta and T1 Bladder Cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s11934-012-0234-4.pdf
Reference32 articles.
1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289.
2. •• Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 59:997. The European agreement in the management of pT1G3 has been updated this edition. Now, European guidelines recommend re-TUR of T1 high-risk bladder cancer.
3. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41:523.
4. •• Divrik RT, Sahin AF, Yildirim U et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 58:185. This study showed that second TUR decreased the recurrence and progression rates in patients with newly diagnosed T1 disease compared to patients with T1 disease but with no second TUR.
5. El-Abbady AA, Shoukry MS, Hanno AG, et al. Repeated transurethral resection of recurrent superficial bladder tumors–does it affect the spread and stage of the tumor? Scand J Urol Nephrol. 2002;36:60.
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer;World Journal of Urology;2024-08-12
2. BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer;Current Oncology;2024-02-16
3. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022;Journal of the National Comprehensive Cancer Network;2022-08
4. Emerging treatment landscape of non-muscle invasive bladder cancer;Expert Opinion on Biological Therapy;2022-05-31
5. Factores de riesgo de enfermedad residual en la re-RTU en una gran cohorte de pacientes con enfermedad T1G3;Actas Urológicas Españolas;2021-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3